Anglais
Arabic
Jad WAKIM
Chargé (e) d’enseignement
Faculté de médecine
+961 (1) 421 000 jad.wakim2@usj.edu.lb
Dr Jad Wakim is a Hematologist-Oncologist trained at the University of Texas Southwestern its NCI-designated Comprehensive Cancer Center. He is double American Board Certified in Medical Oncology Hematology.
Dr. Wakim was the Director of Sweetwater Cancer Center in Rock Springs, WY for 5 years, affiliated with the Huntsman Cancer Institute, before moving back to his native Lebanon where he joined Hotel-Dieu de France University Hospital Clemenceau Medical Center Affiliated with John Hopkins International. He is a lecturer at the University of Utah Saint Joseph University Faculty of Medicine.
He has earned numerous awards for clinical achievements and presentations, and has published many papers and book chapters
Education
| Diplôme | Université | Pays | Année |
|---|---|---|---|
| Doctorat d'exercice - Médecine | |||
| Diplôme de Formation médicales spécialisée - Oncology & Hematologi |
Enseignement universitaire hors USJ
| Enseignement universitaire hors USJ | Pays | Etablissement | Date début | Date fin |
|---|---|---|---|---|
| Internal Medicine & Hematology-Oncology Clinical Instructor, University of Utah, Huntsman Cancer Institute | Etats-Unis | |||
| Internal Medicine Chief Resident, SUNY Upstate Medical University Hospital | Etats-Unis |
Expérience professionnelle hors USJ
| Expérience professionnelle | Organisation | Date début | Date fin |
|---|---|---|---|
| Hematologist-Oncologist, Hotel-Dieu de France University Hospital | Hotel-Dieu de France University Hospital | 2018-04-01 | 2024-11-11 |
| Hematologist-Oncologist, Clemenceau Medical Center | Clemenceau Medical Center | 2017-10-01 | 2024-11-11 |
| Medical Director, Hematologist-Oncologist, Sweetwater Regional Cancer Center, an Affiliate of Huntsman Cancer Institute, University of Utah, NCI-Designated Comprehensive Cancer Center | Sweetwater Regional Cancer Center, an Affiliate of Huntsman Cancer Institute, University of Utah, NCI-Designated Comprehensive Cancer Center | 2012-08-01 | 2017-09-30 |
| Hematologist-Oncologist, St Michael Hospital Cancer Center, Texarkana, TX, USA | St Michael Hospital Cancer Center, Texarkana, TX, USA | 2021-01-07 | 2022-06-30 |
| Hematologist-Oncologist, Northern Light Health-Eastern Maine Medical Center, Bangor, ME, USA | Northern Light Health-Eastern Maine Medical Center, Bangor, ME | 2022-01-01 | 2024-09-30 |
Domaine d’expertise
Médecine et Santé
Thématiques de recherche
Targeted Therapies Immunotherapy: Neuro, ENT, Breast, Gynecological, Pulmonary, Digestive, Urinary, Sarcomas, Dermatology, Benign Malignant Hematology
Publications et communications
Genetic markers of chronic lymphocytic leukemia: a retrospective study of 312 patients from a reference center in Lebanon. Future Oncology 2023 Sep19(29):1991-2002.
Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey. Future Oncology 2021 Nov 17(31):4071-4079.
Helou S., Helou E., Abou-Khalil V., Wakim J., et al. The effect of the COVID-19 pandemic on physicians’ use perception of telehealth: The case of Lebanon. Int. J. Environ. Res. Public Health 2020, 17, 4866
Chaudary P., Wakim J., Khadim H., Karumbaiah KK., Gajra A. Acquired factor X deficiency in systemic amyloidosis: management of two cases. Haemophilia, 2013 Nov 19(6): e375-6.
Wakim JJ., Levenson BM., Matthews D., Naina H. Management of an unusual case of intravascular large B-cell lymphoma of the penis, prostate, bones with CNS relapse. Journal of Clinical Oncology, 2013 June 1031(17):e288-9.
Wakim JJ., Tirado CA., Dowell J., and Chen W. The first case of Philadelphia-negative acute promyelocytic leukemia following imatinib for chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 2012 March;205(3): p124-127.
Wakim JJ. and Tirado CA (January 2012). Acute promyelocytic leukemia lacking the classic translocation t(15;17). In: Koschmieder, S. and Krug, U. (Editors). Myeloid Leukemia – Clinical Diagnosis and Treatment. Chapter 12, p219-234. Intech.
Wakim JJ., Tirado CA., Chen W., and Collins R. t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. Leukemia Research, 2011
Sep;35(9):e151-3